Characteristics of study groups and outcomes for RE-LY Trial
BID indicates twice daily; D, dabigatran etexilate; RR, relative risk; CI, confidence interval; TIA, transient ischemic attack; MI, myocardial infarction; CHF, congestive heart failure; ASA, aspirin.
Outcomes of interest are highlighted in bold.
Sign In or Create an Account